Proleukin and Combivir drug interactions - a phase IV clinical study of FDA data
Summary:
Drug interactions are reported among people who take Proleukin (aldesleukin) and Combivir (lamivudine; zidovudine). Common drug interactions include pyrexia among females and abdominal pain among males.
The phase IV clinical study analyzes what interactions people have when they take Proleukin and Combivir. It is created by eHealthMe based on reports of 24 people who take the same drugs from the FDA, and is updated regularly.
What is Proleukin?
Proleukin has active ingredients of aldesleukin. eHealthMe is studying from 1,865 Proleukin users. Check the latest studies of Proleukin.
What is Combivir?
Combivir has active ingredients of lamivudine; zidovudine. It is often used in hiv infection. eHealthMe is studying from 15,450 Combivir users. Check the latest studies of Combivir.
24 people who take Proleukin and Combivir together, and have interactions are studied.

What are the common drug interactions of Proleukin and Combivir, by gender? *:
female:
- Pyrexia (fever)
- Aphasia (damage to the parts of the brain that control language)
- Mental impairment (a condition affecting the body, perhaps through sight or hearing loss, a mobility difficulty or a health condition)
- Confusion
- Convulsions (muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled of muscles contract and relax rapidly and repeatedly)
- Dermatitis (inflammation of the skin resulting from direct irritation by an external agent or an allergic reaction to it)
- Encephalitis (inflammation of the brain)
- Fatigue (feeling of tiredness)
- Lethargy (tiredness)
male:
- Abdominal pain
- Blood amylase increased
- Blood triglycerides increased
- Cardiac failure congestive
- Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
- Ejection fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat)
- Electrocardiogram abnormal
- Electrocardiogram st segment elevation
- Hypoaesthesia (reduced sense of touch or sensation)
- Influenza like illness
What are the common drug interactions of Proleukin and Combivir, by age (0-1 to 60+)? *:
0-1:
n/a
2-9:
n/a
10-19:
n/a
20-29:
n/a
30-39:
- Flatulence (flatus expelled through the anus)
- Food poisoning (poison in food)
- Gastric erosions (gradual destruction of surface layer of the membrane lining the stomach)
- Heart rate increased
- Injection site erythema (redness at injection site)
- Lethargy (tiredness)
- Loss of consciousness
- Lung infiltration (a substance that normally includes fluid, inflammatory exudates or cells that fill a region of lung)
- Meningitis (inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges)
- Metabolic disorder (an abnormal function and pattern of body fat. insulin resistance refers to the diminished ability of cells to respond to the action of insulin in promoting the transport of the sugar glucose, from blood into muscles and other tissues)
40-49:
- Blood triglycerides increased
- Cardiac failure congestive
- Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
- Ejection fraction (the percentage of blood that is pumped out of a filled ventricle as a result of a heartbeat)
- Electrocardiogram abnormal
- Electrocardiogram st segment elevation
- Gamma-glutamyltransferase increased
- Hypoaesthesia (reduced sense of touch or sensation)
- Mitral valve incompetence (inefficient heart valve)
- Myocardial ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased)
50-59:
- Abdominal pain
- Blood amylase increased
- Weight decreased
- Abdominal mass (localized enlargement or swelling in the human abdomen)
- Anorexia (eating disorder characterized by immoderate food restriction and irrational fear of gaining weight)
- Asthenia (weakness)
- Blood alkaline phosphatase increased
- Blood bilirubin increased
- Cd8 lymphocytes increased
- Cytolytic hepatitis (dissolution or destruction of a liver cell)
60+:
n/a
What are the existing conditions these people have? *
- Hiv Infection: 9 people, 37.50%
- High Blood Pressure: 2 people, 8.33%
- Hepatitis Viral: 2 people, 8.33%
* Approximation only. Some reports may have incomplete information.
Do you take Proleukin and Combivir?
- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously
Related studies:
Effectiveness of, side effects of, and alternative drugs to the 2 drugs:
Browse all drug interactions of Proleukin and Combivir:
a b c d e f g h i j k l m n o p q r s t u v w x y zSub-studies by gender and age:
Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+
Browse all side effects of Proleukin:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Combivir:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Proleukin and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all interactions between Combivir and drugs from A to Z:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study uses data from the FDA. It is based on aldesleukin and lamivudine; zidovudine (the active ingredients of Proleukin and Combivir, respectively), and Proleukin and Combivir (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Drug interactions of Maxzide and Avandia - 4 seconds ago
- Osteoporosis and Panic Reaction - 6 seconds ago
- Beclovent vs. Spiriva Respimat, side effect and effectiveness comparison - 13 seconds ago
- Could Hctz cause Emphysema? - 21 seconds ago
- Could Benadryl cause Infusion Site Infection? - 30 seconds ago
- Could Benadryl cause Febrile Nonhaemolytic Transfusion Reaction? - 31 seconds ago
- Drug interactions of Fluticasone Propionate and Incruse Ellipta - 37 seconds ago
- Renal Cell Carcinoma and Brain Natriuretic Peptide Increased - 51 seconds ago
- Drug interactions of Fluconazole and Maxalt-Mlt - 51 seconds ago
- Febrile Neutropenia and Constipation - 53 seconds ago